Teleflex Incorporated (TFX) Cash Flow Statement

The OCF/NI ratio swung wildly, from -5.72 in 2026Q1 to 7.26 in 2024Q1, reflecting impairment-driven net losses rather than operational deterioration. In 2025Q4, OCF of $152.2M against a net loss of -$714.3M suggests that reported losses are largely non-cash, but the volatility in OCF itself—ranging from $7.7M to $231.0M—indicates inconsistent cash generation. Investors should monitor whether the gap between net income and OCF narrows as impairment charges subside.

The erratic FCF trajectory, including a negative quarter in 2025Q2, suggests that Teleflex's cash generation is not yet stable despite a rebound to $114.7M in 2026Q2. The 2026Q2 FCF margin of 20.1% is respectable, but the prior quarter's 8.5% and the negative print in 2025Q2 indicate that the company has not consistently converted revenue into cash. This volatility may reflect working capital swings and one-time items, warranting a longer-term view to assess true FCF power.

Teleflex's capital expenditure is relatively low for a medical device manufacturer, suggesting a lighter asset base or a shift toward less capital-intensive operations. However, the negative CapEx figures in several quarters (e.g., -$34.6M in 2025Q2) are unusual and may indicate asset sales or timing effects, which could distort the true maintenance capex requirement. The low capital intensity implies that FCF is less constrained by heavy reinvestment, but investors should verify whether this level sustains product innovation.

The large swings in working capital, particularly the -$140.9M drag in 2025Q2 and the +$164.1M boost in 2025Q4, indicate that Teleflex's cash flow is heavily influenced by inventory, receivables, and payables timing. These fluctuations may reflect channel inventory adjustments or supply chain disruptions, but they obscure the underlying cash generation. The 2026Q2 positive $14.9M contribution suggests some normalization, yet the pattern remains unpredictable, complicating cash flow forecasting.

The substantial share repurchases, totaling over $545M in two quarters, appear aggressive given the volatile operating cash flow and negative net income in some periods. This suggests a commitment to returning capital to shareholders, but it may strain liquidity if cash generation falters. The steady dividend, though modest, adds to the cash outflow, and investors should monitor whether buybacks are funded by debt or cash reserves, as the data does not specify the source.

The massive divergence between cumulative OCF and net income is primarily due to impairment charges in 2025Q3 and 2025Q4, which totaled over $1.1B. This suggests that the company's underlying cash-generating ability is stronger than reported earnings imply, but it also raises questions about the sustainability of those impairments and whether future write-downs could recur. The positive OCF despite net losses indicates that the core business is still generating cash, but the earnings quality remains clouded by these charges.